102 results
8-K
ATXI
Avenue Therapeutics Inc
15 Mar 24
Other Events
7:15am
for our intellectual property; our ability to attract and retain key personnel; availability of reimbursement for our products; estimates
424B3
ATXI
Avenue Therapeutics Inc
2 Feb 24
Prospectus supplement
12:00am
License Agreement including reimbursement payments of up to $10.8 million in connection with the product’s Phase 1b/2a clinical trial.
In connection
8-K
EX-99.1
h4ymqig
8 Jan 24
Entry into a Material Definitive Agreement
5:28pm
8-K
pn22v
24 Nov 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
1:19pm
8-K
EX-99.1
5xu0lwwbxn8474 n1
13 Nov 23
Avenue Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights
4:10pm
8-K
EX-10.1
otssbuowmv
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-99.2
cj31ezwpmw
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-4.4
unj866udaxooyygea
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-99.1
97oy6x3bwkr5f0njmwc1
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
8-K
EX-10.2
00ylfx7em3w1x
2 Nov 23
Avenue Therapeutics Announces Pricing of $5.0 Million Public Offering
4:10pm
424B4
ixop2v3
2 Nov 23
Prospectus supplement with pricing info
9:00am